The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,939.00
Bid: 1,938.00
Ask: 1,939.00
Change: 7.00 (0.36%)
Spread: 1.00 (0.052%)
Open: 1,926.00
High: 1,948.00
Low: 1,904.00
Prev. Close: 1,932.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Pandemic fears pummel European stocks into correction territory

Thu, 27th Feb 2020 09:58

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)

* Travel and leisure, basic resources stocks worst hit

* WPP leads losses on STOXX 600 after bleak forecast

* Standard Chartered, AB InBev latest victims of virus
damage

* Hikma Pharma tops STOXX 600 on annual earnings beat
(Adds details, updates to close)

By Ambar Warrick and Thyagaraju Adinarayan

Feb 27 (Reuters) - European stocks marked their weakest
close in more than four months on Thursday, sinking into
correction territory as a jump in coronavirus cases outside
China deepened fears of an economically damaging pandemic.

Investors typically consider a correction in a security or
index to be a drop of 10% or more from its recent peak.

The pan-European STOXX 600 index, which retreated
3.8% for the day, has fallen more than 10% from a record high
hit on Feb. 19.

While strong earnings had caused investors to pause selling
on Wednesday, a spike in infections outside China, particularly
in Italy, saw markets slip back into red.

"From the unshakeable optimism seen at the beginning of the
year, investors have done a complete U-turn switching from
excessive optimism to outright pessimism in less than a week,"
Michael Hewson, chief market analyst at CMC Markets UK, said.

Thursday's sell-off saw more than 97% of the pan-European
STOXX 600 index's constituents trading red, with basic
resources stocks among the worst performers as commodity
prices plunged amid fears of sustained disruptions in the global
supply chain.

"The sell-off in the base metals complex over the last few
days largely reflects the heightened risk-off sentiment or
'fear-factor' across broader riskier assets," Wenyu Yao, senior
commodities strategist at ING wrote in a note.

London-listed miner Evraz Plc was the worst
performing stock in the sector after it posted weak 2019
earnings.

Travel stocks also plummeted, with casino operator
Evolution Gaming Group leading declines. The sector
has shed nearly 15% this week, underperforming its peers by a
wide margin.

Standard Chartered fell 3.5% after the bank said a
key earnings target would take longer to meet as the epidemic
adds to headwinds in China and Hong Kong. The broader bank
sector was also pressured by a drop in bond yields.

The world's largest beer maker, Anheuser-Busch InBev
, plunged nearly 11% after it forecast muted growth in
2020, due in part to the outbreak.

Advertising major WPP tumbled 16%, marking its worst
day since August 1992, after saying it would target flat organic
growth and profit margins in 2020. The stock was the worst
performer on the STOXX 600.

Italian shares, which entered correction territory
on Wednesday, fell 2.7% as the country reported another 100
coronavirus cases nationwide, taking the total to more than 400.

In a sole bright spot, Hikma Pharmaceuticals rose
4.6%, topping the STOXX 600 after it beat expectations with its
annual earnings.
(Reporting by Sruthi Shankar in Bengaluru and Danilo Masoni in
Milan
Editing by Sriraj Kalluvila, Giles Elgood and Frances Kerry)

More News
6 Aug 2021 12:07

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

Read more
6 Aug 2021 09:03

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

Read more
6 Aug 2021 08:40

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

Read more
6 Aug 2021 07:42

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

Read more
6 Aug 2021 07:22

Hikma lifts FY generics guidance as first-half profits, revenue jump

(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.

Read more
30 Jul 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jul 2021 19:38

IN BRIEF: Arecor ends first half of 2021 with solid cash position

IN BRIEF: Arecor ends first half of 2021 with solid cash position

Read more
13 Jul 2021 10:00

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

Read more
1 Jul 2021 09:51

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

Read more
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more
30 Apr 2021 17:01

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Read more
30 Apr 2021 08:58

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.